Abstract
Antithrombotic therapy in acute coronary syndrome without ST-segment elevation should be initiated with aspirin 100 mg/day (loading dose 250-500 mg) and Clopidogrel 75 mg/day (loading dose 300 mg). In addition, anticoagulation with unfractionated heparin or low molecular weight heparin should be started. A GP IIb/IIIa receptor blocker can be given either upfront (Eptifibatide/Tirofiban) or directly in the cathlab preceding PCI (Abciximab). Aspirin should be given in the chronic phase lifelong, Clopidogrel for at least nine months. An invasive strategy is recommended in high-risk patients within 48 hours.
MeSH terms
-
Acute Disease
-
Angina, Unstable / diagnosis*
-
Angina, Unstable / drug therapy
-
Angina, Unstable / surgery
-
Angina, Unstable / therapy*
-
Anticoagulants / therapeutic use*
-
Coronary Disease / diagnosis*
-
Coronary Disease / drug therapy
-
Coronary Disease / surgery
-
Coronary Disease / therapy*
-
Decision Support Techniques
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Myocardial Infarction / diagnosis*
-
Myocardial Infarction / drug therapy
-
Myocardial Infarction / surgery
-
Myocardial Infarction / therapy*
-
Patient Care Management / methods
-
Practice Patterns, Physicians'
-
Risk Assessment / methods
-
Syndrome
-
Treatment Outcome
Substances
-
Anticoagulants
-
Fibrinolytic Agents